Ticker: LLY | Published: 2026-09-23
Lilly drifts lower calmly
Lilly is slipping moderately on low volatility with normal volume, and the news mix is balanced, with an FDA approval for an oral breast cancer drug and a Houston plant expanding GLP-1 capacity offsetting the mild selling pressure.
Sources: https://www.healthline.com/health-news/fda-approves-eli-lilly-oral-combo-drug-common-breast-cancer-mutation, https://w